Table 2 Difficulties/frustrations reported by 102 specialist physicians who were involved in the management of Quebec's 2009 pH1N1
Have you experienced difficulties/frustrations? | IDMM (n = 62) n (%) | PHPMS (n = 40) n (%) |
|---|---|---|
Overall categories | 52 (84.0%) | 35 (87.5%) |
Patients' management - clinical level | ||
Overall | 49 (79.0%) | 10 (25%) |
Beds management | 16 (25.8%) | 0 |
Case reporting | 19 (30.6%) | 2 (5.0%) |
Laboratories | 40 (64.5%) | 3 (7.5%) |
Patients care | 25 (40.3%) | 1 (2.5%) |
Treatment | 24 (38.7%) | 2 (5.0%) |
Infection prevention and control | 36 (58.1%) | 6 (15.0%) |
Other | 1 (1.6%) | 0 |
Patients' management - Public Health level | ||
Overall | 28 (45.2%) | 22 (55%) |
Expert committees | 12 (19.4%) | 9 (22.5%) |
Case reporting | 12 (19.4%) | 7 (17.5%) |
Epidemiological investigations | 9 (14.5%) | 10 (25.0%) |
Neuraminidase inhibitors prescriptions | 17 (27.4%) | 5 (12.5%) |
Other | 2 (3.2%) | 8 (20.0%) |
Crisis management | ||
Overall | 28 (45.2%) | 24 (60%) |
Top-down | 23 (37.1%) | 22 (55.0%) |
Quebec-Canada | 11 (17.7%) | 4 (10.0%) |
Other | 1 (1.6%) | 2 (5.0%) |
Communication process | ||
Overall | 34 (54.8%) | 24 (60%) |
Clinical practice guidelines (content) | 19 (30.6%) | 11 (27.5%) |
Dissemination of clinical practice guidelines | 26 (41.9%) | 13 (32.5%) |
Communication routes | 25 (40.3%) | 12 (30.0%) |
Other | 2 (3.2%) | 2 (5.0%) |
Vaccination | ||
Overall | 35 (56.4%) | 25 (62.5%) |
Availability of vaccine | 21 (33.9%) | 10 (25.0%) |
Groups at risk | 18 (29.0%) | 17 (42.5%) |
Number of dosage | 11 (17.7%) | 3 (7.5%) |
Administration approach | 16 (25.8%) | 8 (20.0%) |
Other | 5 (8.1%) | 4 (10.0%) |
Management of pandemic waves | ||
Overall | 31 (50%) | 11 (27.5%) |
Availability of epidemiological data on cases | 11 (17.7%) | 7 (17.5%) |
Cases management | 9 (14.5%) | 3 (7.5%) |
Laboratories organization | 27 (43.5%) | 1 (5.0%) |
Other | 1 (1.6%) | 3 (7.5%) |
Other issues not previously covered | ||
Overall | 7 (11.2%) | 6 (15.0%) |